Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Six Patent Applications Related to RNAi: May 1, 2008

Premium
Title: microRNAs and Methods for Inhibiting the Same
 
Number: 7,365,058
 
Filed: April 13, 2004
 
Lead Inventor: Markus Stoffel, Rockefeller University (Alnylam Pharmaceuticals)
 
“The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA,” the patent’s abstract states. “In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.”
 

 
Title: Encapsulated Nanoparticles for Drug Delivery
 
Number: 20080095856
 
Filed: May 14, 2007
 
Lead Inventor: Gunilla Jacobson, Stanford University
 
The patent application, its abstract states, claims “compositions and methods … for preparing nano-sized biologically active agents, including agents formulated for target-specific drug delivery. The nano-sized agents are prepared with supercritical carbon dioxide as an antisolvent, providing nanoparticles whose size, shape, and surroundings are well-controlled. The nanoparticles are made of small molecules … [or] polynucleotides [such as] siRNA.”
 

 
Title: Small Interfering RNA and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same
 
Number: 20080096839
 
Filed: March 9, 2006 PCT Filed: March 9, 2006
 
Lead Inventor: Meehyein Kim, Mogam Biotechnology Research Institute
 
The invention “relates to RNA interference-mediated inhibition of hepatitis B virus by short interfering RNA molecules,” the patent application’s abstract states. “Specially, siRNAs of the … invention, which are double-stranded RNAs, concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the … invention.”
 

 
Title: siRNA Targeting Deubiqutination Enzymes
 
Number: 20080097089
 
Filed: Oct. 25, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for deubiquitination enzymes.”
 

 
Title: Functional and Hyperfunctional siRNA Directed Against Bcl-2
 
Number: 20080097090
 
Filed: Oct. 17, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent applications’ abstracts state. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing Bcl-2.”
 

 
Title: siRNA Targeting TNF-Alpha
 
Number: 20080097091
 
Filed: Oct. 22, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” according to the patent application’s abstract. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TNF-alpha.”
 

 
Title: siRNA Targeting Kinases
 
Number: 20080097092
 
Filed: Oct. 23, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” according to the patent application’s abstract. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for kinases.”

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.